Anne serves as Chief Financial Officer at Topas. She brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe. She also served as the CFO and Co-Founder of Breath Therapeutics GmbH, where she was instrumental in securing the financing (EUR 43.5 million) as well as executing the sale of the company to Zambon S.p.A. in 2019, with a deal value up to EUR 500 million. Previously, Anne served as CFO at Rigontec and had an active role in the execution of Rigontec’s trade sale to MSD (known as Merck & Co. in North America), a deal worth up to EUR 464 million. Throughout her career, Anne has been responsible for corporate fundraising, executing trade sales and licensing agreements, and preparing for IPOs in several senior executive and advisory roles in the life sciences industry. Anne holds a graduate degree in Business Administration from Ludwig-Maximilians-University in Munich and has completed graduate studies in public health.